F1 Oncology Affiliate EXUMA biotechnology Acquires CAR-T Assets.
M2 EQUITYBITES-November 16, 2018-F1 Oncology Affiliate EXUMA biotechnology Acquires CAR-T Assets
(C)2018 M2 COMMUNICATIONS http://www.m2.com
16 November 2018 - Hong Kong-based biotechnology company EXUMA has acquired all rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets for the development and commercialisation of cellular therapies in Greater China to be used in the treatment of solid tumor malignancies, the company said.
Terms of the transaction were not disclosed.
EXUMA is an international affiliate of US-based F1 Oncology, Inc., a biotech company discovering and developing adoptive cellular therapies for solid tumors.
F1 Oncology said the decision to integrate these programmers and processes into EXUMA was driven by the favorable early clinical profile, and the company will support its advancement toward multicentre trials next year.
EXUMA Biotech integrates BioAtla's conditionally active biologic protein therapeutic technology with F1 Oncology's proprietary CAR-T technologies to develop and commercialise CAB-CAR-T therapies and other ACTs for the treatment of solid tumor malignancies.
F1 Oncology, Inc. is a private Delaware corporation that leverages its globally integrated science, development and informatics teams to accelerate the design, high-throughput screening, discovery and development of adoptive cellular therapy candidates.
EXUMA biotechnology, a clinical-stage biotechnology company developing CAR-T solutions for the solid tumor markets in Asia, was formed as a Cayman Special Economic Zone company with capitalisation and exclusive technology licenses from F1 Oncology, Inc.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 16, 2018|
|Previous Article:||AKKA Closes Acquisition of PDS Tech in the United States.|
|Next Article:||Corsearch Acquires Yellow Brand Protection to Expand Digital Solutions Platform.|